The available evidence, as summarized from research since 2005, is that LBM loss, while proportionate to fat loss and possibly adaptive, nonetheless remains a concern for muscle function and the risk of long-term sarcopenia, especially with SGLT2 inhibitors, where meta-analyses pose the risk of possible losses of strength. Here, SLC5A2 is linked to sarcopenia.